Coronary Stents Market: Market Size & Forecast 2026

Coronary stents are medical devices used in interventional cardiology to treat coronary artery disease by keeping arteries open after angioplasty. The market encompasses bare-metal stents, drug-eluting stents, and bioresorbable vascular scaffolds, with drug-eluting variants representing the largest segment due to superior clinical outcomes. Valued at approximately $14.25 billion in 2025, the market reflects sustained demand from rising cardiovascular disease burden and procedural volume growth across both developed and developing healthcare systems.

• •Market size estimated at $14.25 billion in 2025 with steady expansion projected through the decade
• •Drug-eluting stents command dominant market share over bare-metal and bioresorbable alternatives
• •Procedural volume growth linked to increasing coronary artery disease prevalence globally

The primary growth catalyst is the escalating global burden of cardiovascular diseases, particularly coronary artery disease, which remains the leading cause of death worldwide according to World Health Organization data. Sedentary lifestyles, dietary shifts, and aging demographics contribute to rising incidence rates, especially in Asia-Pacific and Latin American regions. Additionally, technological advancements in stent materials and drug-coating technologies have improved clinical outcomes, driving physician preference and patient adoption.

• •Rising prevalence of coronary artery disease linked to aging populations and lifestyle-related risk factors
• •Improved stent designs offering better biocompatibility and reduced restenosis rates
• •Expanding access to percutaneous coronary interventions in emerging markets

The market is segmented by stent type into drug-eluting stents, bare-metal stents, and bioresorbable vascular scaffolds, with drug-eluting stents holding the majority share due to lower re-intervention rates. Geographically, North America and Europe constitute mature markets with high procedure volumes and reimbursement coverage, while Asia-Pacific emerges as the fastest-growing region driven by improving healthcare infrastructure and rising disease burden. Key regional markets include the United States, Germany, Japan, China, and India, each characterized by distinct regulatory environments and adoption patterns.

• •Drug-eluting stents represent the largest product category by revenue
• •Asia-Pacific registers fastest growth due to rising healthcare spending and disease prevalence
• •North America maintains largest regional share with established interventional cardiology networks

What are the recent trends and outlook?

Emerging trends include the development of bioresorbable scaffolds intended to restore natural vessel function after drug delivery, though adoption has faced clinical challenges. Next-generation drug-eluting stents with thinner struts and biocompatible polymers are gaining traction, while value-based procurement models increasingly influence purchasing decisions in price-sensitive markets. The outlook remains positive with ongoing procedural volume growth, though pricing pressure from healthcare cost containment initiatives may moderate revenue expansion in certain regions.

• •Next-generation thinner-strut drug-eluting stents improving deliverability and clinical outcomes
• •Bioresorbable technology evolving with improved scaffold designs under clinical investigation
• •Healthcare cost containment measures creating pricing pressure in mature markets